CXCR4 is a G-protein-coupled receptor involved in a number of physiological processes in
the hematopoietic and immune systems. The SDF-1/CXCR4 axis is significantly associated …

Abstract AMD3100 (plerixafor), a CXCR4 antagonist, has opened a variety of avenues for
potential therapeutic approaches in different refractory diseases. The CXCL12/CXCR4 axis …

The identification of phenotypically distinct HIV-1 variants with different prevalence during
the progression of the disease has been one of the earliest discoveries in HIV-1 biology, but …

Abstract (See the Editorial Commentary by Loes, on pages 1280–2.) Background. In the
context of sexual transmission of human immunodeficiency virus type 1 (HIV-1), current …

Abstract (See the editorial commentary by Hodskog and Albert, on pages 163–5.)
Background. The prevalence and correlates of CXCR4-use in recently diagnosed patients …

Background While initiation of highly active antiretroviral therapy (HAART) during primary
HIV-1 infection occasionally results in transient control of viral replication after treatment …

Abstract CXCR4 antagonists (eg, PlerixaforTM) have been successfully validated as stem
cell mobilizers for peripheral blood stem cell transplantation. Applications of the CXCR4 …

Allogeneic hematopoietic stem and progenitor cell transplant (HSCT) of CCR5 null
(CCR5Δ32) cells can be curative for HIV-1-infected patients. However, because allogeneic …

Introduction. Specific molecular epidemic features of HIV infection in Tyumen Oblast (TO),
Russia, were studied. Methods. The genome sequences encoding HIV‐1 protease‐reverse …

Cell entry by HIV-1 is mediated by its principal receptor, CD4, and a coreceptor, either CCR5
or CXCR4, with viral envelope glycoprotein gp120. Generally, CCR5-using HIV-1 variants …